Universal DX Raises €62M for AI Cancer Detection Tech

In a significant boost for early cancer detection technology, Spanish firm Universal DX has successfully closed a substantial funding round, attracting a total of €62 million. Leading the investment is the Sociedad Española para la Transformación Tecnológica (SETT), a public entity under the Ministry for Digital Transformation and Public Function, which injected €29.9 million. This strategic infusion of capital is earmarked to accelerate the development and commercialization of Universal DX's innovative AI-powered diagnostic platform.

The substantial investment from SETT, channeled through its Next Tech facility and funded by the European Union's Recovery, Transformation, and Resilience Plan (Next Generation EU funds), underscores a strong governmental commitment to advancing digital health solutions. This public-private collaboration aims to propel cutting-edge startups and scale-ups within the technology sector. The deal was formally finalized by Javier Ponce, Director General of SETT, and Diego Broseta, CFO of Universal DX.

Universal DX, also known as Universal Diagnostics (UDX), specializes in next-generation diagnostics, focusing on early cancer detection via liquid biopsy. The company's proprietary technology leverages a sophisticated combination of artificial intelligence, machine learning, and molecular analysis to identify subtle patterns in blood DNA, offering unparalleled precision. This approach analyzes multiple biological information layers, providing a more comprehensive view of a patient's tumor status than traditional methods.

This advanced analytical capability, coupled with a state-of-the-art digital infrastructure featuring automated laboratory processes and big data management, allows UDX to achieve significantly higher sensitivity in detecting early-stage colorectal cancer and precancerous lesions. The company is currently finalizing regulatory approval for its flagship colorectal cancer test and is actively developing similar assays for lung, liver, pancreatic, and esophageal cancers, with plans to expand its European presence in a subsequent phase.

The development of UDX's sophisticated algorithms has been supported by collaborations with numerous Spanish academic institutions, including the Polytechnic University of Catalonia, the Polytechnic University of Valencia, and the Institute of Mathematics of the University of Seville (IMUS). This strong research foundation positions Universal DX as a pioneer in the competitive oncology diagnostics market, a sector projected for significant growth driven by increasing demand for non-invasive and accurate screening methods.

This funding round is particularly noteworthy within the broader context of healthtech innovation. The global market for AI in healthcare is expanding rapidly, with diagnostics being a key area of focus. Companies like Universal DX are at the forefront, addressing critical unmet needs in early disease detection, which is proven to dramatically improve patient outcomes and reduce healthcare costs. The successful capital raise by Universal DX signals strong investor confidence in the potential of AI to revolutionize medical diagnostics and highlights Spain's growing role in fostering deep-tech advancements.